Mustang Bio (MBIO) AI Stock Analysis

• Market Cap: $6.19M
• Dividend Yield: N/A
• Average Volume (3M): 94.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.14
• Revenue Growth: N/A
• EPS Growth: 98.58%
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 6,453,701
• 10 Day Avg. Volume: 88,215
• 30 Day Avg. Volume: 94,141
• PEG Ratio: 0.30
• Price to Book (P/B): 5.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.15
• Enterprise Value/Market Cap: -2.07
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 312.59
• Enterprise Value/Ebitda: 6.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $0.85 ▼(-22.11% Downside)
• Action: Reiterated Date: 03/20/26
• Date: Action: Reiterated 03/20/26

The score is mainly driven by improved financial trajectory (narrowing losses and reduced cash burn) and a low-debt balance sheet, offset by continued lack of revenue and negative free cash flow. Technicals remain weak with the stock trading below major moving averages, and valuation signals are constrained by persistent losses and no dividend support.

Positive Factors

Improved balance sheet (no debt)

The company reports zero reported debt in the trailing twelve months and a recovery of equity to roughly $9.8M from negative levels. This recapitalization materially improves solvency and financial flexibility, reducing near-term default risk and supporting continued clinical investment.

Sharply reduced net losses

A multi-year decline in annual net losses shows successful cost reduction and program prioritization. Narrowing losses lengthen runway per financing round and indicate management can slow burn while advancing key programs, lowering dilutive financing needs over the medium term.

Equity plans expand talent retention

Approval to expand employee equity and incentive plans strengthens the company’s ability to attract and retain specialized scientific and clinical staff. For a clinical-stage biotech, sustained access to talent is a durable operational advantage that supports trial execution and program continuity.

Negative Factors

Pre-revenue business model

Mustang remains essentially pre-revenue, meaning it lacks product-derived cash flows to fund operations. This structural reliance on capital markets or partners increases execution risk over the next several months and constrains self-funded expansion of clinical programs.

Negative operating and free cash flow

Persistent negative operating and free cash flow requires ongoing external financing to sustain R&D and trials. Although burn has improved, continued outflows create funding dependency that can force dilution, program delays, or reprioritization if capital markets tighten.

Balance-sheet volatility and financing risk

Historical swings from high leverage to recent recapitalization indicate volatility in funding access. Such variability signals refinancing and dilution risk during adverse markets, which is a structural constraint on long-term program funding and strategic optionality.

Mustang Bio Business Overview & Revenue Model

Company Description

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

How the Company Makes Money

Mustang Bio has historically generated little to no recurring revenue from product sales because it has not consistently had approved, marketed therapies. As a clinical-stage biotech, its primary funding has generally come from financing activities (e.g., issuing equity and/or other securities) and, where applicable, proceeds related to strategic transactions. Specific, ongoing revenue streams such as product sales, recurring service revenue, or material royalty/licensing income are not reliably available as a stable business model based on public high-level company characterization alone; therefore, detailed breakdowns of recurring operating revenue streams, named significant commercial partnerships that materially drive earnings, and product-based monetization details are null.

Mustang Bio Financial Statement Overview

Summary

Losses and cash burn have improved sharply over recent years and the company currently carries no debt, but it still has no revenue and continues to generate negative free cash flow, implying ongoing reliance on external funding and elevated dilution/runway risk.

Income Statement

The company reports no revenue across the annual periods provided, consistent with a pre-commercial biotech profile. Losses have narrowed materially over time (net loss improving from about -$77.5M in 2022 and -$51.6M in 2023 to -$15.8M in 2024 and -$1.9M in 2025), indicating significant cost reduction or restructuring progress. However, profitability remains negative with ongoing operating losses, and the absence of revenue limits visibility into sustainable earnings power.

Balance Sheet

Leverage is currently low with total debt at $0 in 2025 and equity positive at ~$9.5M, which reduces near-term balance-sheet risk. That said, the equity base has been volatile (including negative equity in 2024 and extremely high leverage in 2023 when equity was near zero), highlighting historical financial stress and dilution/restructuring risk. Total assets have also declined meaningfully from prior years, suggesting a smaller remaining operating/asset base.

Cash Flow

Cash burn remains the key issue: operating cash flow and free cash flow are negative in every year shown. The burn rate has improved substantially (free cash flow from roughly -$68.1M in 2022 and -$49.6M in 2023 to -$11.4M in 2024 and -$5.3M in 2025), which is a clear positive trajectory. Still, with continuing negative free cash flow and no revenue, the business likely remains dependent on external funding or strategic transactions to sustain operations.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-41.00K	0.00	-2.23M	-3.03M	-2.31M
EBITDA	-2.39M	-14.92M	-48.06M	-71.14M	-64.05M
Net Income	-1.92M	-15.75M	-51.60M	-77.53M	-66.37M
Balance Sheet
Total Assets	17.59M	9.31M	17.74M	92.42M	125.17M
Cash, Cash Equivalents and Short-Term Investments	17.27M	6.84M	6.23M	75.66M	109.62M
Total Debt	0.00	878.00K	2.50M	31.38M	2.03M
Total Liabilities	8.06M	13.18M	17.62M	46.15M	12.77M
Stockholders Equity	9.53M	-3.87M	123.00K	46.27M	112.40M
Cash Flow
Free Cash Flow	-5.26M	-11.41M	-49.59M	-68.14M	-59.03M
Operating Cash Flow	-5.26M	-11.41M	-49.48M	-65.07M	-53.67M
Investing Cash Flow	1.17M	0.00	5.89M	-2.95M	-5.37M
Financing Cash Flow	14.53M	11.27M	-26.08M	34.06M	70.85M

Mustang Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MBIO, the sentiment is Negative. The current price of 1.09 is above the 20-day moving average (MA) of 0.95, above the 50-day MA of 0.95, and below the 200-day MA of 1.35, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 38.41 is Neutral, neither overbought nor oversold. The STOCH value of 29.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MBIO.

Mustang Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACXP	53 Neutral	$15.99M	-0.47	-291.07%	―	―	61.10%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MBIO	50 Neutral	$6.19M	-25.06	-418.83%	―	―	98.58%
SLXN	44 Neutral	$4.06M	-0.21	-529.06%	―	―	91.47%
LYRA	41 Neutral	$869.69K	-0.48	-1032.82%	―	-59.21%	68.97%
BOLT	41 Neutral	$9.15M	-0.31	-97.58%	―	-46.88%	34.83%
XTLB	39 Underperform	$6.39M	-5.27	―	―	―	65.45%

Mustang Bio Corporate Events

Mustang Bio Shareholders Approve Equity Plans and Directors

At its 2025 Annual Meeting of stockholders held virtually on December 22, 2025, Mustang Bio shareholders approved all four proposals on the agenda, including the election of seven directors to serve until the 2026 annual meeting and the ratification of KPMG LLP as the company’s independent auditor for the year ending December 31, 2025. Investors also backed amendments to Mustang’s 2019 Employee Stock Purchase Plan, adding 250,000 issuable shares and increasing the shares subject to a Purchase Right to 10,000, and to its 2016 Incentive Plan, expanding the pool of issuable shares by 2,500,000, moves that enhance the company’s ability to use equity compensation in attracting and retaining talent. Separately, on December 17, 2025, Mustang and Fred Hutchinson Cancer Center agreed to terminate their CD20 License Agreement covering Mustang’s CD20 CAR-T program, with Mustang paying $730,000 to settle about $1.4 million in outstanding payables, and securing the right to receive at least 10% of any future consideration Fred Hutch obtains from third-party licenses of the former CD20 assets over the next three years, preserving some upside despite exiting the program.